Meningococcal meningitis serogroups A, C, Y & W-135 Diphtheria conjugate vaccine (NmVac4-A/C/Y/W-135-DT™) 

Welcome to JN-International Medical Corporation, a U.S. based private  biopharmaceutical corporation, has been developing vaccines for infectious disease and neurological disorders. Emphasis on our 20-years of basic research combined with an applied focus on specific medical needs was instrumental to success and growth of this corporation.  The style of JN, our new corporate website, reflects our values and gives information on our principle business areas. So happy reading!

Do you Kmow?

JN is the 3rd BioPharma, developed patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4dt) which is now human phase.

Who We Are

JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNIMC) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore. JNI partners with Global Health Organizations such as the Clinton Global Initiative,,the Global Business Coalition, New York, President's Malaria Initiative and PEPFAR. JNI also partners with several other non-profit global health organizations, NGOs, local governments and communities in developing countries to address the health issues related to HIV AIDS Malaria Tuberculosis and Bacterial Meningitis that scourges the underserved communities in West Africa, South East Asia and Latin America.